menu
    • menu
    [{"orgOrder":0,"company":"Serb","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Naxitamab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Serb","amount2":0.40999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"Infusion","sponsorNew":"Serb \/ Serb","highestDevelopmentStatusID":"15","companyTruncated":"Serb \/ Serb"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"BELGIUM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Serb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Serb \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serb \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Serb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Serb \/ Serb","highestDevelopmentStatusID":"15","companyTruncated":"Serb \/ Serb"},{"orgOrder":0,"company":"Serb","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Bentracimab","moa":"Ticagrelor","graph1":"Hematology","graph2":"Phase III","graph3":"Serb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Serb \/ Serb","highestDevelopmentStatusID":"10","companyTruncated":"Serb \/ Serb"}]

    Find Clinical Drug Pipeline Developments & Deals by Serb

    Menu

    Serb

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Serb

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Serb

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naxitamab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Y-mAbs Therapeutics

                            Deal Size : $412.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

                            Details : Through the acquisition, SERB will leverage Y-mAbs pipeline, including its lead commercial oncology asset, Danyelza (naxitamab). It is being indicated for neuroblastoma.

                            Product Name : Danyelza

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $412.0 million

                            August 05, 2025

                            Lead Product(s) : Naxitamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Y-mAbs Therapeutics

                            Deal Size : $412.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Serb

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Serb

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bentracimab

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Recipient : SFJ Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            SERB Pharmaceuticals and SFJ Pharmaceuticals Announce a U.S. Partnership for Bentracimab, a Ticagrelor

                            Details : Through the acquisition, SERB has acquired exclusive US rights to the ticagrelor reversal agent PB2452 (bentracimab), a novel, monoclonal antibody fragment, from SFJ. SFJ will remain responsible for the ongoing trials of bentracimab and will work with SE...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            May 11, 2023

                            Lead Product(s) : Bentracimab

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Recipient : SFJ Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Serb

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Serb

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SERB Receives Positive CHMP Opinion for Voraxaze® (Glucarpidase) as Rescue Therapy for High Dose Methotrexate...

                            Details : Company recieved positive opinion of CHMP of Voraxaze® (glucarpidase) based on clinical data and real world experience. Voraxaze reduces toxic plasma methotrexate concentration in adults and children may quickly lower MTX levels and avoid further system...

                            Product Name : Voraxaze

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            November 25, 2021

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Serb

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Serb

                            Belgium arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Recipient : BTG Specialty Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            SERB Completes Acquisition of BTG Specialty Pharmaceuticals to Create a Global Leader in Critical Care Medicin...

                            Details : BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®.

                            Product Name : Voraxaze

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            March 02, 2021

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Recipient : BTG Specialty Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth